Generate:Biomedicines advanced its lead AI‑discovered TSLP (thymic stromal lymphopoietin) antibody into Phase III studies, marking a notable late‑stage milestone for an AI‑designed therapeutic. The company said the decision follows robust earlier‑phase efficacy and safety data and will initiate two large pivotal trials to support registration. Generate’s program is being watched as a test of AI‑driven discovery’s ability to reach definitive clinical proof points. The company emphasized that its generative design platform accelerated candidate selection and optimization, shortening the preclinical timeline compared with traditional discovery routes. Investors and partner companies will treat the Phase III readouts as a key validation point for AI‑first biotech approaches; a positive result would strengthen the commercial case for AI‑discovered biologics.